REVIEW

Substance use during pregnancy [version 1; peer review: 2 approved]

Ariadna Forray

Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA

V1 First published: 13 May 2016, 5(F1000 Faculty Rev):887
<https://doi.org/10.12688/f1000research.7645.1>

Latest published: 13 May 2016, 5(F1000 Faculty Rev):887
<https://doi.org/10.12688/f1000research.7645.1>

Abstract

Prenatal substance use is a critical public health concern that is linked with several harmful maternal and fetal consequences. The most frequently used substance in pregnancy is tobacco, followed by alcohol, cannabis and other illicit substances. Unfortunately, polysubstance use in pregnancy is common, as well as psychiatric comorbidity, environmental stressors, and limited and disrupted parental care, all of which can compound deleterious maternal and fetal outcomes. There are few existing treatments for prenatal substance use and these mainly comprise behavioral and psychosocial interventions. Contingency management has been shown to be the most efficacious of these. The purpose of this review is to examine the recent literature on the prenatal use of tobacco, alcohol, cannabis, stimulants, and opioids, including the effects of these on maternal and fetal health and the current therapeutic options.

Keywords

drug abuse, pregnancy, prenatal substance use

Open Peer Review

Approval Status

	1	2
version 1
13 May 2016		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Oscar Garcia-Algar**, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
2. **Kirsten A. Donald**, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa

Any comments on the article can be found at the end of the article.

Corresponding author: Ariadna Forray (ariadna.forray@yale.edu)

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2016 Forray A. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Forray A. **Substance use during pregnancy [version 1; peer review: 2 approved]** F1000Research 2016, 5 (F1000 Faculty Rev):887 <https://doi.org/10.12688/f1000research.7645.1>

First published: 13 May 2016, 5(F1000 Faculty Rev):887 <https://doi.org/10.12688/f1000research.7645.1>

Introduction

In the United States, women comprise 40% of those with a lifetime drug use disorder and 26% of those who meet criteria for both an alcohol and drug use disorder during the prior 12 months¹. Furthermore, women are at highest risk for developing a substance use disorder during their reproductive years (18–44), especially ages 18–29². This means that women who are pregnant or soon to become pregnant are at increased risk for substance abuse. According to a national survey conducted in the United States in 2012, 5.9% of pregnant women use illicit drugs, 8.5% drink alcohol and 15.9% smoke cigarettes³, resulting in over 380,000 offspring exposed to illicit substances, over 550,000 exposed to alcohol and over one million exposed to tobacco in utero. Similar patterns of use have been observed in Europe^{4,5} and Australia⁶. The most commonly used substance in pregnancy is nicotine, followed by alcohol, marijuana and cocaine^{7,8}. However, polysubstance use is as high as 50% in some studies^{7,9}. Recently, there has been an increase in opiate use in pregnancy. Between 2000 and 2009, the United States saw a five-fold increase in opiate use in pregnancy, coincident with an “epidemic” of opiate prescription misuse^{10–12}.

There is little information available on the extent of substance use, other than tobacco, among pregnant women in low-income and middle-income countries. The overall prevalence of tobacco use in these countries is 2.6%, with some countries having much higher maternal rates—up to 15%¹³. While data on illicit substance use in pregnancy is lacking for most middle- and low-income countries, according to the World Health Organization, cannabis is the most common illicit drug worldwide, followed by amphetamine-type stimulants and opiates¹⁴, and, as such, they are likely to be used by women of reproductive age. The limited data available for Africa is from South Africa, and indicates that between 3.6 and 8.8% of pregnant women use illicit substances and 19.6% use alcohol¹⁵. The most commonly used illicit substances in South Africa include methamphetamine and cannabis¹⁶. Opiate use has also increased in places like Africa and Asia¹⁷, and is likely to become more prevalent in pregnancy.

Prenatal substance use can bring about several deleterious consequences for both mother and baby, as described in detail below. The concern for the impact of substances on the developing fetus can motivate some women to curb their drug and alcohol use during pregnancy¹⁸. In the only prospective study on prenatal substance use, 96% of women with heavy drinking, 78% of women with marijuana use, 73% of women with cocaine use, and 32% of cigarette smokers succeeded in achieving abstinence during pregnancy⁹. Offsetting the reduction in pregnancy-related use is the dramatic rise in substance use from 6 to 12 months postpartum⁹. The study showed relapse in 58% of abstinent smokers, 51% of abstinent women who used alcohol, 41% of abstinent women who used marijuana and 27% of abstinent women who used cocaine in the 3 months following delivery⁹. Thus, while the levels of abstinence in pregnancy may be high, the impact of this is diminished due to the high rates of relapse postpartum. Unfortunately, maternal relapse happens at a time of high childcare needs and when infant development is dependent on maternal bonding. It is also important to note that this was a study conducted in the United States and that the levels of abstinence may not be equivalent in other

countries, especially middle- and low-income countries where women may encounter significant socioeconomic stressors, low levels of education, and limited available treatments for substance use.

As evidenced by these data, substance use in pregnancy is still a critical public health concern. The purpose of this review is to provide a brief overview of the pregnancy outcomes, neonatal and long-term developmental consequences of prenatal substance use, and current available treatments for pregnant women.

Adverse effects of substance use in pregnancy

Heavy alcohol use in pregnancy has been associated with a range of negative birth outcomes, including increased risks of miscarriage¹⁹, stillbirth and infant mortality^{20,21}, congenital anomalies²², low birthweight²³, reduced gestational age²⁴, preterm delivery²⁵, and small-for-gestational age^{22,26,27}. The evidence for low to moderate alcohol use in pregnancy has either been inconclusive²⁸ or shown no increased risk for these adverse pregnancy outcomes²⁹. Alcohol use in pregnancy has the most well established adverse fetal health effects^{30–32} and is associated with the development of fetal alcohol spectrum disorders^{33–35} and adverse neurodevelopmental outcomes³⁶. In addition, prenatal drinking is associated with long-term effects, such as cognitive and behavioral challenges^{37,38}, adverse speech and language outcomes³⁹, executive functioning deficits in children⁴⁰, and psychosocial consequences in adulthood⁴¹.

Smoking during pregnancy exerts direct adverse effects on birth outcomes, including damage to the umbilical cord structure⁴², miscarriage⁴³, increased risk for ectopic pregnancy⁴⁴, low birthweight^{45–47}, placental abruption^{45,46,48}, preterm birth^{45,49}, and increased infant mortality^{45,46,48}. Also of concern are the deleterious health effects of second-hand smoke on newborns, which include higher rates of respiratory and ear infections, sudden infant death syndrome, behavioral dysfunction and cognitive impairment⁵⁰. Additionally, women who were smokers before pregnancy might stop breastfeeding early so that they can take up smoking again⁵¹.

Some pregnant women view cannabis use as harmless in pregnancy⁵²; however, it has been linked with several deleterious effects, including preterm labor, low birthweight, small-for-gestational age, and admission to the neonatal intensive care unit⁵³. Prenatal cannabis use has also been linked with adverse consequences for the growth of fetal and adolescent brains⁵², reduced attention and executive functioning skills, poorer academic achievement and more behavioral problems⁵⁴. The adverse effects of marijuana are frequently observed with comorbid substance use, and are greatest in heavy users.

The extent of the adverse effects of cocaine use in pregnancy has been overestimated at times. However, there have been several large and thorough studies recently, which have all identified several risk factors associated with cocaine use during pregnancy, including premature rupture of membranes, placental abruption, preterm birth, low birthweight, and small for gestational age infants^{55,56}. There have been inconsistent reports on the long-term effects of prenatal cocaine exposure on language, motor, and cognitive development, with a few studies describing positive findings^{57,58} and some studies reporting very little or no effects⁵⁹. This inconsistency

is probably connected to the confounding effects of the postnatal environment, including unsteady and disordered home environments, dysfunctional parenting, and heavy maternal polysubstance use^{60–62}. Similar to cocaine use in pregnancy, methamphetamine use is linked with shorter gestational ages, lower birthweight⁶³, fetal loss⁶⁴, developmental and behavioral defects⁶⁵, preeclampsia, gestational hypertension, and intrauterine fetal death⁶⁶.

Opioid use in pregnancy is correlated with a greater risk of low birthweight, respiratory problems, third trimester bleeding, toxemia and mortality^{12,67}. Maternal opiate use is associated with an increased risk of neonatal abstinence syndrome (NAS), whereby opiate exposure in utero triggers a postnatal withdrawal syndrome¹². Anywhere from 45 to 94% of infants exposed to opioids in utero, including methadone and buprenorphine, can be affected by NAS¹². NAS results in substantial neonatal morbidity and increased healthcare utilization^{12,67}, and consists of an array of signs and symptoms, including irritability, feeding difficulties, tremors, hypertonia, emesis, loose stools, seizures, and respiratory distress⁶⁸. Opioid exposure in pregnancy has also been associated with postnatal growth deficiency, microcephaly, neurobehavioral problems, and sudden infant death syndrome⁶⁷. Cigarette smoking, which is very common in pregnant women with an opioid use disorder (77–95%)^{69,70}, may confound the effect of opioid use on poor pregnancy outcomes.

A significant point to take into account is that the undesirable consequences of prenatal substance use are confounded by the frequency of coexisting substance use and comorbid psychiatric illness^{71,72}. Women with substance use disorders also frequently experience inadequate prenatal care, poor nutrition, chronic medical problems, poverty, and domestic violence^{73,74}. Furthermore, substance use in pregnancy may also result in an early dysfunctional maternal-infant relationship that can potentiate the negative effects of prenatal drug exposure^{60,61}.

Treatment of substance use in pregnancy

There are only a small number of effective therapies for substance use in pregnancy, which primarily involve behavioral counseling (see Table 1). Brief interventions⁷⁵, in particular those that utilize motivational interviewing^{76,77}, have been shown to reduce prenatal alcohol use. A recent randomized trial utilizing a telephone-based

brief intervention suggests that this method may achieve similar results to the in-person intervention method of moderating prenatal drinking⁷⁸. Some additional interventions to reduce prenatal drinking that have recently been described include screening via non-healthcare community workers⁷⁹, counseling by midwives⁸⁰, and multimedia and educational efforts aimed at improving awareness⁸¹.

As with alcohol, behavioral counseling is the main treatment for smoking cessation and relapse prevention in pregnant women. Unfortunately, psychotherapeutic interventions have had only moderate success^{82–85}. Pharmacological treatments for smoking cessation have not been evaluated with respect to their safety and efficacy in pregnant and postpartum women^{82,86}. Randomized clinical trials with nicotine replacement therapy in pregnant women have demonstrated limited efficacy in increasing the rates of abstinence^{87–90}. The most successful intervention for prenatal smoking cessation is contingency management (CM) with financial incentives^{91–93}, which has also reportedly improved birth outcomes⁹⁴.

Treatments specifically aimed at prenatal cannabis use are lacking. The current recommendation for lowering the use of cannabis in pregnancy includes the screening of pregnant women to increase the early identification of cannabis use⁵². Motivational interviewing (MI)^{95,96}, cognitive-behavioral therapy (CBT)^{95–99}, and CM therapies have had some success in reducing marijuana use in women, but they have not been evaluated specifically with pregnant users. Thus, novel interventions that explicitly target cannabis use are vital, particularly given the current tendency towards marijuana legalization.

Existing evidence-based treatments for cocaine use in pregnancy include CBT, MI and CM¹⁰⁰. As with smoking, CM is the intervention that shows most potential for treating cocaine-using pregnant women⁶². A randomized trial found that CM was associated with much longer duration of cocaine abstinence, higher number of cocaine-negative urine tests, and a greater proportion of documented abstinence when compared to community reinforcement approach and twelve-step facilitation¹⁰¹. Currently, there are no evidence-based pharmacological treatments for prenatal cocaine use. Nevertheless, a recent randomized, placebo-controlled trial

Table 1. Description of behavioral interventions for substance use disorders.

Contingency management (CM)	Based on the principle of positive reinforcement as a means of operant conditioning to influence behavior change. The premise behind CM is to systematically use reinforcement techniques, usually monetary vouchers, to modify behavior in a positive and supportive manner. Originally used for the treatment of cocaine users, it has since been used for opioids, marijuana, cigarettes, alcohol, benzodiazepines, and other drugs.
Motivational interviewing (MI)	A patient-centered, collaborative and highly empathic counselling style for eliciting behavior change by helping clients to explore and resolve ambivalence. It draws from the trans theoretical model of change in order to improve treatment readiness and retention.
Cognitive Behavioral Therapy (CBT)	A psychotherapeutic treatment that uses an easy-to-learn set of strategies to help patients understand the situations that lead them to undesirable thoughts, feelings, or behaviors, to then avoid those situations when possible, and to deal more effectively with such situations when they occur. The goal of these strategies is to break old patterns of responding and replace them with new ones.

supports the use of oral micronized progesterone as an intervention for postpartum cocaine use¹⁰². The study showed that women randomized to placebo had more self-reported cocaine use compared to women receiving micronized progesterone during the 12 weeks of the trial¹⁰². While these are preliminary findings and will require confirmation in a larger clinical trial, they show promise for the application of progesterone in postpartum women to reduce their cocaine use. Treatments for other stimulant use, such as methamphetamine, are limited. Research into reinforcement-based therapy (RBT) combined with a women-focused intervention among pregnant methamphetamine users reported a reduction in methamphetamine use over time¹⁰³. However, there were no substantial distinctions between the intervention and control conditions¹⁰³, not unlike another study using RBT to treat stimulant use in pregnancy¹⁰⁴. RBT seems to have potential as an intervention for methamphetamine use but more research is required.

Methadone maintenance is the standard care for pregnant women with opiate use disorders¹⁰⁵. Conversion from illicit opioid use to opioid maintenance therapy in a medically supervised setting decreases maternal and neonatal morbidity. Methadone maintenance offers greater relapse prevention with a steady opioid dosing regimen, reduces risk-taking behavior, enhances compliance with prenatal care, and leads to better neonatal outcomes¹⁰⁶. On the other hand, medication-assisted withdrawal, that is detoxification by gradually reducing the dose of an opioid substitute medication, is associated with a high opioid relapse rate and higher fetal morbidity and mortality rates¹⁰⁶. Buprenorphine has recently emerged as another potential therapy for opioid use in pregnancy. A randomized controlled trial that compared methadone and buprenorphine in pregnant opioid users showed that infants whose mothers received buprenorphine needed less treatment for NAS, substantially lower doses of morphine to treat NAS symptoms, and had shorter stays in hospital, compared to the infants of women given methadone¹⁰⁷. Notably, buprenorphine had lower retention rates with flexibly delivered doses and low fixed doses compared to methadone¹⁰⁸. However, buprenorphine and methadone are equally effective when given as fixed medium or high doses¹⁰⁸. CM has likewise been reported to be effective in treating opioid use in pregnancy, by significantly increasing abstinence and treatment attendance compared to controls¹⁰⁹. Thus, CM appears to be an important addition to methadone or buprenorphine treatment in pregnant women.

Breastfeeding and postpartum substance use

Breastfeeding has the potential to be a useful tool for substance use in the postpartum period. Breastfeeding is the only available intervention shown to reduce NAS severity in opioid-exposed newborns^{110,111}. Breastfeeding might also be protective for postpartum relapse. For example, among breastfeeding smokers, 10% stop breastfeeding because of smoking, and over half of recent or current smokers reported that smoking affected their infant feeding decision¹¹². In addition, non-current smokers are more likely to initiate and continue breastfeeding compared to current smokers^{113,114}.

Therefore, the promotion of breastfeeding might prevent or delay postpartum relapse.

While studies evaluating the potential role of breastfeeding as an intervention for substance use postpartum are limited, the rationale for such interventions is clear. Lactation reduces the HPA response to physical stress¹¹⁵. A behavior that promotes relaxation and reduces stress would be helpful to women with substance use disorders since psychosocial stress increases cravings¹¹⁶. While hormones released during lactation may mediate stress reduction, such hormones have other properties that may help women cope with addiction. Considerable attention has been dedicated to oxytocin, a hormone released during delivery and lactation. Oxytocin administration is under investigation for treatment of drug and alcohol use disorders^{116–118}. In addition, lactation is positively associated with cognitive and motor development in the infant¹¹⁹. It is well known that stable attachment among children increases resiliency and protects against the development of addiction later in life^{120,121}. Thus, an intervention that promotes lactation and intimacy through skin-to-skin contact may enhance stable attachment, and have the intergenerational benefit of protecting offspring from the development of addictive and other problematic behaviors^{120,122,123}.

Conclusions

Substance use in pregnancy remains a significant public health problem, which can lead to several harmful maternal and neonatal outcomes. Which drug is being used and the degree of use, as well as the point of exposure, all influence the effects of drug use in pregnancy. In addition to the direct effects of drug exposure in utero, several other variables are associated with deleterious maternal and infant consequences, including psychiatric comorbidity, polysubstance use, limited prenatal care, environmental stressors and disrupted parental care. In conjunction, these factors can negatively influence pregnancy and infant outcomes, and should be taken into account when developing interventions for prenatal substance use treatments. Many of the health problems associated with substance use in the prenatal period could be avoided given effective and well-timed medical care or intervention. Empirically-driven interventions for prenatal substance use are needed. While there are few treatment options for substance use in pregnancy, CM seems to show the greatest promise as an effective therapy for the substances in which it has been studied. Future research needs to focus on developing tailored, safe, and acceptable treatments that can capitalize on pregnancy as a “teachable” moment that can motivate women to adopt risk-reducing health behaviors^{124–127}.

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1. Stinson FS, Grant BF, Dawson DA, *et al.*: Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Drug Alcohol Depend.* 2005; **80**(1): 105–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Compton WM, Thomas YF, Stinson FS, *et al.*: Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Arch Gen Psychiatry.* 2007; **64**(5): 566–576.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. United States Department of H, Human Services. Substance A, Mental Health Services Administration. Center for Behavioral Health S Quality: **National Survey on Drug Use and Health, 2012.** Inter-university Consortium for Political and Social Research (ICPSR) [distributor]. 2013.
[Publisher Full Text](#)
4. (EMCDDA) EMCiDaDA: **The State of the Drugs Problem in Europe.** Luxembourg. 2011.
[Publisher Full Text](#)
5. El Marroun H, Tiemeier H, Jaddoe VW, *et al.*: Demographic, emotional and social determinants of cannabis use in early pregnancy: the Generation R study. *Drug Alcohol Depend.* 2008; **98**(3): 218–226.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Passey ME, Sanson-Fisher RW, D'Este CA, *et al.*: Tobacco, alcohol and cannabis use during pregnancy: clustering of risks. *Drug Alcohol Depend.* 2014; **134**: 44–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Ebrahim SH, Grover J: **Pregnancy-related substance use in the United States during 1996–1998.** *Obstet Gynecol.* 2003; **101**(2): 374–379.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Howell EM, Heiser N, Harrington M: **A review of recent findings on substance abuse treatment for pregnant women.** *J Subst Abuse Treat.* 1999; **16**(3): 195–219.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Forray A, Merry B, Lin H, *et al.*: **Perinatal substance use: a prospective evaluation of abstinence and relapse.** *Drug Alcohol Depend.* 2015; **150**: 147–155.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Hayes MJ, Brown MS: **Epidemic of prescription opiate abuse and neonatal abstinence.** *JAMA.* 2012; **307**(18): 1974–1975.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Desai RJ, Hernandez-Diaz S, Bateman BT, *et al.*: **Increase in prescription opioid use during pregnancy among Medicaid-enrolled women.** *Obstet Gynecol.* 2014; **123**(5): 997–1002.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Patrick SW, Schumacher RE, Benneyworth BD, *et al.*: **Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009.** *JAMA.* 2012; **307**(18): 1934–1940.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Caleyachetty R, Tai CA, Kengne AP, *et al.*: **Tobacco use in pregnant women: analysis of data from Demographic and Health Surveys from 54 low-income and middle-income countries.** *Lancet Glob Health.* 2014; **2**(9): e513–e520.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Organization WH: **World Drug Report.** United Nations Office on Drugs and Crime; 2012.
[Reference Source](#)
15. Petersen Williams P, Jordaan E, Mathews C, *et al.*: **Alcohol and Other Drug Use during Pregnancy among Women Attending Midwife Obstetric Units in the Cape Metropole, South Africa.** *Adv Prev Med.* 2014; **2014**: 871427.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Jones HE, Browne FA, Myers BJ, *et al.*: **Pregnant and nonpregnant women in Cape Town, South Africa: drug use, sexual behavior, and the need for comprehensive services.** *Int J Pediatr.* 2011; **2011**: 353410.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Degenhardt L, Whiteford HA, Ferrari AJ, *et al.*: **Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010.** *Lancet.* 2013; **382**(9904): 1564–1574.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Higgins PG, Clough DH, Frank B, *et al.*: **Changes in health behaviors made by pregnant substance users.** *Int J Addict.* 1995; **30**(10): 1323–1333.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Armstrong BG, McDonald AD, Sloan M: **Cigarette, alcohol, and coffee consumption and spontaneous abortion.** *Am J Public Health.* 1992; **82**(1): 85–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. O'Leary C, Jacoby P, D'Antoine H, *et al.*: **Heavy prenatal alcohol exposure and increased risk of stillbirth.** *BJOG.* 2012; **119**(8): 945–952.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Strandberg-Larsen K, Grønboek M, Andersen AM, *et al.*: **Alcohol drinking pattern during pregnancy and risk of infant mortality.** *Epidemiology.* 2009; **20**(6): 884–891.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Rosett HL, Weiner L, Lee A, *et al.*: **Patterns of alcohol consumption and fetal development.** *Obstet Gynecol.* 1983; **61**(5): 539–546.
[PubMed Abstract](#)
23. Passaro KT, Little RE, Savitz DA, *et al.*: **The effect of maternal drinking before conception and in early pregnancy on infant birthweight. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood.** *Epidemiology.* 1996; **7**(4): 377–383.
[PubMed Abstract](#)
24. Sulaiman ND, Florey CD, Taylor DJ, *et al.*: **Alcohol consumption in Dundee primigravidae and its effects on outcome of pregnancy.** *Br Med J (Clin Res Ed).* 1988; **296**(6635): 1500–1503.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. O'Leary CM, Nassar N, Kurinczuk JJ, *et al.*: **The effect of maternal alcohol consumption on fetal growth and preterm birth.** *BJOG.* 2009; **116**(3): 390–400.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Mills JL, Graubard BI, Harley EE, *et al.*: **Maternal alcohol consumption and birth weight. How much drinking during pregnancy is safe?** *JAMA.* 1984; **252**(14): 1875–1879.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Whitehead N, Lipscomb L: **Patterns of alcohol use before and during pregnancy and the risk of small-for-gestational-age birth.** *Am J Epidemiol.* 2003; **158**(7): 654–662.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Henderson J, Gray R, Brocklehurst P: **Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome.** *BJOG.* 2007; **114**(3): 243–252.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Lundsberg LS, Illuzzi JL, Belanger K, *et al.*: **Low-to-moderate prenatal alcohol consumption and the risk of selected birth outcomes: a prospective cohort study.** *Ann Epidemiol.* 2015; **25**(1): 46–54.e3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Srikanth VM, O'Leary CM: **Pregnancy outcomes of mothers with an alcohol-related diagnosis: a population-based cohort study for the period 1983–2007.** *BJOG.* 2015; **122**(6): 795–804.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. DeVido J, Bogunovic O, Weiss RD: **Alcohol use disorders in pregnancy.** *Harv Rev Psychiatry.* 2015; **23**(2): 112–121.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Waterman EH, Pruett D, Caughey AB: **Reducing fetal alcohol exposure in the United States.** *Obstet Gynecol Surv.* 2013; **68**(5): 367–378.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Hankin JR: **Fetal alcohol syndrome prevention research.** *Alcohol Res Health.* 2002; **26**(1): 58–65.
[PubMed Abstract](#)
34. Esper LH, Furtado EF: **Identifying maternal risk factors associated with Fetal Alcohol Spectrum Disorders: a systematic review.** *Eur Child Adolesc Psychiatry.* 2014; **23**(10): 877–889.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Fox DJ, Pettygrove S, Cuniff C, *et al.*: **Fetal alcohol syndrome among children aged 7-9 years - Arizona, Colorado, and New York, 2010.** *MMWR Morb Mortal Wkly Rep.* 2015; **64**(3): 54–57.
[PubMed Abstract](#)
36. Vall O, Salat-Battle J, Garcia-Algar O: **Alcohol consumption during pregnancy and adverse neurodevelopmental outcomes.** *J Epidemiol Community Health.* 2015; **69**(10): 927–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Green CR, Roane J, Hewitt A, *et al.*: **Frequent behavioural challenges in children with fetal alcohol spectrum disorder: a needs-based assessment reported by caregivers and clinicians.** *J Popul Ther Clin Pharmacol.* 2014; **21**(3): e405–420.
[PubMed Abstract](#)
38. Bakoyannis I, Gkioka E, Pergialiotis V, *et al.*: **Fetal alcohol spectrum disorders and cognitive functions of young children.** *Rev Neurosci.* 2014; **25**(5): 631–639.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. **F** O'Keeffe LM, Greene RA, Kearney PM: **The effect of moderate gestational alcohol consumption during pregnancy on speech and language outcomes in children: a systematic review.** *Syst Rev.* 2014; **3**: 1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
40. Fuglestad AJ, Whitley ML, Carlson SM, *et al.*: **Executive functioning deficits in preschool children with Fetal Alcohol Spectrum Disorders.** *Child Neuropsychol.* 2015; **21**(6): 716–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Rangmar J, Hjern A, Vinnerljung B, *et al.*: **Psychosocial outcomes of fetal alcohol syndrome in adulthood.** *Pediatrics.* 2015; **135**(1): e52–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. **F** Rua Ede A, Porto ML, Ramos JP, *et al.*: **Effects of tobacco smoking during pregnancy on oxidative stress in the umbilical cord and mononuclear blood cells of neonates.** *J Biomed Sci.* 2014; **21**: 105.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
43. **F** Pineles BL, Park E, Samet JM: **Systematic review and meta-analysis of**

- miscarriage and maternal exposure to tobacco smoke during pregnancy.** *Am J Epidemiol.* 2014; 179(7): 807–823.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
44. **F** Horne AW, Brown JK, Nio-Kobayashi J, *et al.*: **The association between smoking and ectopic pregnancy: why nicotine is BAD for your fallopian tube.** *PLoS One.* 2014; 9(2): e89400.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 45. Salihi HM, Wilson RE: **Epidemiology of prenatal smoking and perinatal outcomes.** *Early Hum Dev.* 2007; 83(11): 713–720.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Cnattingius S: **The epidemiology of smoking during pregnancy: smoking prevalence, maternal characteristics, and pregnancy outcomes.** *Nicotine Tob Res.* 2004; 6(Suppl 2): S125–140.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Quesada O, Gotman N, Howell HB, *et al.*: **Prenatal hazardous substance use and adverse birth outcomes.** *J Matern Fetal Neonatal Med.* 2012; 25(8): 1222–1227.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Tikkanen M, Nuutila M, Hillesmaa V, *et al.*: **Prepregnancy risk factors for placental abruption.** *Acta Obstet Gynecol Scand.* 2006; 85(1): 40–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Ion R, Bernal AL: **Smoking and Preterm Birth.** *Reprod Sci.* 2015; 22(8): 918–926.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. DiFranza JR, Aligne CA, Weitzman M: **Prenatal and postnatal environmental tobacco smoke exposure and children's health.** *Pediatrics.* 2004; 113(4 Suppl): 1007–1015.
[PubMed Abstract](#)
 51. Ratner PA, Johnson JL, Bottorff JL: **Smoking relapse and early weaning among postpartum women: is there an association?** *Birth.* 1999; 26(2): 76–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Jaques SC, Kingsbury A, Henschke P, *et al.*: **Cannabis, the pregnant woman and her child: weeding out the myths.** *J Perinatol.* 2014; 34(6): 417–424.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Hayatbakhsh MR, Flenady VJ, Gibbons KS, *et al.*: **Birth outcomes associated with cannabis use before and during pregnancy.** *Pediatr Res.* 2012; 71(2): 215–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Warner TD, Roussos-Ross D, Behnke M: **It's not your mother's marijuana: effects on maternal-fetal health and the developing child.** *Clin Perinatol.* 2014; 41(4): 877–894.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 55. Addis A, Moretti ME, Ahmed Syed F, *et al.*: **Fetal effects of cocaine: an updated meta-analysis.** *Reprod Toxicol.* 2001; 15(4): 341–369.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Gouin K, Murphy K, Shah PS: **Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses.** *Am J Obstet Gynecol.* 2011; 204(4): 340.e1–e12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Chaplin TM, Freiburger MB, Mayes LC, *et al.*: **Prenatal cocaine exposure, gender, and adolescent stress response: a prospective longitudinal study.** *Neurotoxicol Teratol.* 2010; 32(6): 595–604.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Bandstra ES, Vogel AL, Morrow CE, *et al.*: **Severity of prenatal cocaine exposure and child language functioning through age seven years: a longitudinal latent growth curve analysis.** *Subst Use Misuse.* 2004; 39(1): 25–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. Frank DA, Augustyn M, Knight WG, *et al.*: **Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review.** *JAMA.* 2001; 285(12): 1613–1625.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 60. Mansoor E, Morrow CE, Accornero VH, *et al.*: **Longitudinal effects of prenatal cocaine use on mother-child interactions at ages 3 and 5 years.** *J Dev Behav Pediatr.* 2012; 33(1): 32–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Strathearn L, Mayes LC: **Cocaine addiction in mothers: potential effects on maternal care and infant development.** *Ann N Y Acad Sci.* 2010; 1187: 172–183.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 62. Hull L, May J, Farrell-Moore D, *et al.*: **Treatment of cocaine abuse during pregnancy: translating research to clinical practice.** *Curr Psychiatry Rep.* 2010; 12(5): 454–461.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. **F** Wright TE, Schuetter R, Tellei J, *et al.*: **Methamphetamines and pregnancy outcomes.** *J Addict Med.* 2015; 9(2): 111–117.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 64. **F** Brecht ML, Herbeck DM: **Pregnancy and fetal loss reported by methamphetamine-using women.** *Subst Abuse.* 2014; 8: 25–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 65. **F** Dyk J, Ramanjam V, Church P, *et al.*: **Maternal methamphetamine use in pregnancy and long-term neurodevelopmental and behavioral deficits in children.** *J Popul Ther Clin Pharmacol.* 2014; 21(2): e185–196.
[PubMed Abstract](#) | [F1000 Recommendation](#)
 66. **F** Gorman MC, Orme KS, Nguyen NT, *et al.*: **Outcomes in pregnancies complicated by methamphetamine use.** *Am J Obstet Gynecol.* 2014; 211(4): 429.e1–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 67. Minozzi S, Amato L, Bellisario C, *et al.*: **Maintenance agonist treatments for opiate-dependent pregnant women.** *Cochrane Database Syst Rev.* 2013; 12: CD006318.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Hudak ML, Tan RC, COMMITTEE ON DRUGS, *et al.*: **Neonatal drug withdrawal.** *Pediatrics.* 2012; 129(2): e540–560.
[PubMed Abstract](#) | [Publisher Full Text](#)
 69. Jones HE, Heil SH, Tuten M, *et al.*: **Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes.** *Drug Alcohol Depend.* 2013; 131(3): 271–277.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 70. Chisolm MS, Tuten M, Brigham EC, *et al.*: **Relationship between cigarette use and mood/anxiety disorders among pregnant methadone-maintained patients.** *Am J Addict.* 2009; 18(5): 422–429.
[PubMed Abstract](#) | [Free Full Text](#)
 71. Tuten M, Heil SH, O'Grady KE, *et al.*: **The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients.** *Am J Drug Alcohol Abuse.* 2009; 35(5): 358–363.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 72. Benningfield MM, Arria AM, Kallenbach K, *et al.*: **Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women.** *Am J Addict.* 2010; 19(5): 416–421.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 73. Havens JR, Simmons LA, Shannon LM, *et al.*: **Factors associated with substance use during pregnancy: results from a national sample.** *Drug Alcohol Depend.* 2009; 99(1–3): 89–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
 74. Hutchins E, DiPietro J: **Psychosocial risk factors associated with cocaine use during pregnancy: a case-control study.** *Obstet Gynecol.* 1997; 90(1): 142–147.
[PubMed Abstract](#) | [Publisher Full Text](#)
 75. Chang G, McNamara TK, Orav EJ, *et al.*: **Brief intervention for prenatal alcohol use: a randomized trial.** *Obstet Gynecol.* 2005; 105(5 Pt 1): 991–998.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 76. **F** Osterman RL, Carle AC, Ammerman RT, *et al.*: **Single-session motivational intervention to decrease alcohol use during pregnancy.** *J Subst Abuse Treat.* 2014; 47(1): 10–19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 77. Rendall-Mkosi K, Morojele N, London L, *et al.*: **A randomized controlled trial of motivational interviewing to prevent risk for an alcohol-exposed pregnancy in the Western Cape, South Africa.** *Addiction.* 2013; 108(4): 725–732.
[PubMed Abstract](#) | [Publisher Full Text](#)
 78. Wilton G, Moberg DP, Van Stelle KR, *et al.*: **A randomized trial comparing telephone versus in-person brief intervention to reduce the risk of an alcohol-exposed pregnancy.** *J Subst Abuse Treat.* 2013; 45(5): 389–394.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 79. **F** O'Connor MJ, Rotheram-Borus MJ, Tomlinson M, *et al.*: **Screening for fetal alcohol spectrum disorders by nonmedical community workers.** *J Popul Ther Clin Pharmacol.* 2014; 21(3): e442–452.
[PubMed Abstract](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 80. **F** van der Wulp NY, Hoving C, Eijmael K, *et al.*: **Reducing alcohol use during pregnancy via health counseling by midwives and internet-based computer-tailored feedback: a cluster randomized trial.** *J Med Internet Res.* 2014; 16(12): e274.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 81. **F** Crawford-Williams F, Fielder A, Mikocka-Walus A, *et al.*: **A critical review of public health interventions aimed at reducing alcohol consumption and/or increasing knowledge among pregnant women.** *Drug Alcohol Rev.* 2015; 34(2): 154–161.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 82. Agboola S, McNeill A, Coleman T, *et al.*: **A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers.** *Addiction.* 2010; 105(8): 1362–1380.
[PubMed Abstract](#) | [Publisher Full Text](#)
 83. Heckman CJ, Egleston BL, Hofmann MT: **Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analysis.** *Tob Control.* 2010; 19(5): 410–416.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 84. Levitt C, Shaw E, Wong S, *et al.*: **Systematic review of the literature on postpartum care: effectiveness of interventions for smoking relapse prevention, cessation, and reduction in postpartum women.** *Birth.* 2007; 34(4): 341–347.
[PubMed Abstract](#) | [Publisher Full Text](#)
 85. Reitzel LR, Vidrine JI, Businelle MS, *et al.*: **Preventing postpartum smoking relapse among diverse low-income women: a randomized clinical trial.** *Nicotine Tob Res.* 2010; 12(4): 326–335.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 86. Oncken CA, Kranzler HR: **What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?** *Nicotine Tob Res.* 2009; 11(11): 1265–1273.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 87. **F** Essex HN, Parrott S, Wu Q, *et al.*: **Cost-Effectiveness of Nicotine Patches for Smoking Cessation in Pregnancy: A Placebo Randomized Controlled Trial (SNAP).** *Nicotine Tob Res.* 2015. 17(6): 636–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 88. El-Mohandes AA, Windsor R, Tan S, *et al.*: **A randomized clinical trial of**

- trans-dermal nicotine replacement in pregnant African-American smokers. *Matern Child Health J*. 2013; 17(5): 897–906.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
89. **F** Cooper S, Lewis S, Thornton JG, *et al.*: The SNAP trial: a randomised placebo-controlled trial of nicotine replacement therapy in pregnancy—clinical effectiveness and safety until 2 years after delivery, with economic evaluation. *Health Technol Assess*. 2014; 18(54): 1–128.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
 90. **F** Coleman T, Cooper S, Thornton JG, *et al.*: A randomized trial of nicotine-replacement therapy patches in pregnancy. *N Engl J Med*. 2012; 366(9): 808–818.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
 91. Chamberlain C, O'Mara-Eves A, Oliver S, *et al.*: Psychosocial interventions for supporting women to stop smoking in pregnancy. *Cochrane Database Syst Rev*. 2013; 10: CD001055.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 92. Higgins ST, Washio Y, Heil SH, *et al.*: Financial incentives for smoking cessation among pregnant and newly postpartum women. *Prev Med*. 2012; 55(Suppl): S33–S40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 93. **F** Ierfino D, Mantzari E, Hirst J, *et al.*: Financial incentives for smoking cessation in pregnancy: a single-arm intervention study assessing cessation and gaming. *Addiction*. 2015; 110(4): 680–688.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
 94. **F** Higgins ST, Bernstein IM, Washio Y, *et al.*: Effects of smoking cessation with voucher-based contingency management on birth outcomes. *Addiction*. 2010; 105(11): 2023–2030.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
 95. Hoch E, Bühringer G, Pixa A, *et al.*: CANDIS treatment program for cannabis use disorders: findings from a randomized multi-site translational trial. *Drug Alcohol Depend*. 2014; 134: 185–193.
[PubMed Abstract](#) | [Publisher Full Text](#)
 96. Hoch E, Noack R, Henker J, *et al.*: Efficacy of a targeted cognitive-behavioral treatment program for cannabis use disorders (CANDIS). *Eur Neuropsychopharmacol*. 2012; 22(4): 267–280.
[PubMed Abstract](#) | [Publisher Full Text](#)
 97. Stephens RS, Roffman RA, Simpson EE: Treating adult marijuana dependence: a test of the relapse prevention model. *J Consult Clin Psychol*. 1994; 62(1): 92–99.
[PubMed Abstract](#) | [Publisher Full Text](#)
 98. Carroll KM, Nich C, Lapaglia DM, *et al.*: Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less. *Addiction*. 2012; 107(9): 1650–1659.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 99. Copeland J, Swift W, Roffman R, *et al.*: A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. *J Subst Abuse Treat*. 2001; 21(2): 55–64; discussion 65–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 100. **F** Terplan M, Ramanadhan S, Locke A, *et al.*: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions. *Cochrane Database Syst Rev*. 2015; 4: Cd006037.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
 101. Schottenfeld RS, Moore B, Pantalon MV: Contingency management with community reinforcement approach or twelve-step facilitation drug counseling for cocaine dependent pregnant women or women with young children. *Drug Alcohol Depend*. 2011; 118(1): 48–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
 102. Yonkers KA, Forray A, Nich C, *et al.*: Progesterone Reduces Cocaine Use in Postpartum Women with a Cocaine Use Disorder: A Randomized, Double-Blind Study. *Lancet Psychiatry*. 2014; 1(5): 360–367.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 103. **F** Jones HE, Myers B, O'Grady KE, *et al.*: Initial feasibility and acceptability of a comprehensive intervention for methamphetamine-using pregnant women in South Africa. *Psychiatry J*. 2014; 2014: 929767.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
 104. Jones HE, O'Grady KE, Tuten M: Reinforcement-based treatment improves the maternal treatment and neonatal outcomes of pregnant patients enrolled in comprehensive care treatment. *Am J Addict*. 2011; 20(3): 196–204.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 105. Center for Substance Abuse Treatment: Chapter 13. Medication-Assisted Treatment for Opioid Addiction During Pregnancy. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series, No. 43. 2005.
[Reference Source](#)
 106. Jones HE, O'Grady KE, Malfi D, *et al.*: Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. *Am J Addict*. 2008; 17(5): 372–386.
[PubMed Abstract](#) | [Publisher Full Text](#)
 107. Jones HE, Kallenbach K, Heil SH, *et al.*: Neonatal abstinence syndrome after methadone or buprenorphine exposure. *N Engl J Med*. 2010; 363(24): 2320–2331.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 108. **F** Mattick RP, Breen C, Kimber J, *et al.*: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev*. 2014; 2: CD002207.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
 109. Jones HE, Haug N, Silverman K, *et al.*: The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. *Drug Alcohol Depend*. 2001; 61(3): 297–306.
[PubMed Abstract](#) | [Publisher Full Text](#)
 110. O'Connor AB, Collett A, Alto WA, *et al.*: Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. *J Midwifery Womens Health*. 2013; 58(4): 383–388.
[PubMed Abstract](#) | [Publisher Full Text](#)
 111. Welle-Strand GK, Skurtveit S, Jansson LM, *et al.*: Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. *Acta Paediatr*. 2013; 102(11): 1060–1066.
[PubMed Abstract](#) | [Publisher Full Text](#)
 112. Bogen DL, Davies ED, Bamhart WC, *et al.*: What do mothers think about concurrent breast-feeding and smoking? *Ambul Pediatr*. 2008; 8(3): 200–204.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 113. Edwards N, Sims-Jones N, Breithaupt K: Smoking in pregnancy and postpartum: relationship to mothers' choices concerning infant nutrition. *Can J Nurs Res*. 1998; 30(3): 83–98.
[PubMed Abstract](#)
 114. Liu J, Rosenberg KD, Sandoval AP: Breastfeeding duration and perinatal cigarette smoking in a population-based cohort. *Am J Public Health*. 2006; 96(2): 309–314.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 115. Altemus M, Deuster PA, Galliven E, *et al.*: Suppression of hypothalamic-pituitary-adrenal axis responses to stress in lactating women. *J Clin Endocrinol Metab*. 1995; 80(10): 2954–2959.
[PubMed Abstract](#) | [Publisher Full Text](#)
 116. McRae-Clark AL, Carter RE, Price KL, *et al.*: Stress- and cue-elicited craving and reactivity in marijuana-dependent individuals. *Psychopharmacology (Berl)*. 2011; 218(1): 49–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 117. Pedersen CA, Smedley KL, Leserman J, *et al.*: Intranasal oxytocin blocks alcohol withdrawal in human subjects. *Alcohol Clin Exp Res*. 2013; 37(3): 484–489.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 118. **F** Lee MR, Glassman M, King-Casas B, *et al.*: Complexity of oxytocin's effects in a chronic cocaine dependent population. *Eur Neuropsychopharmacol*. 2014; 24(9): 1483–1491.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
 119. Bernard JY, De Agostini M, Forhan A, *et al.*: Breastfeeding duration and cognitive development at 2 and 3 years of age in the EDEN mother-child cohort. *J Pediatr*. 2013; 163(1): 36–42.e1.
[PubMed Abstract](#) | [Publisher Full Text](#)
 120. Strathearn L: Maternal neglect: oxytocin, dopamine and the neurobiology of attachment. *J Neuroendocrinol*. 2011; 23(11): 1054–1065.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 121. Love TM: Oxytocin, motivation and the role of dopamine. *Pharmacol Biochem Behav*. 2014; 119: 49–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 122. **F** Tops M, Koole SL, Ijzerman H, *et al.*: Why social attachment and oxytocin protect against addiction and stress: Insights from the dynamics between ventral and dorsal corticostriatal systems. *Pharmacol Biochem Behav*. 2014; 119: 39–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
 123. McGregor IS, Bowen MT: Breaking the loop: oxytocin as a potential treatment for drug addiction. *Horm Behav*. 2012; 61(3): 331–339.
[PubMed Abstract](#) | [Publisher Full Text](#)
 124. **F** Bloch M, Parascandola M: Tobacco use in pregnancy: a window of opportunity for prevention. *Lancet Glob Health*. 2014; 2(9): e489–490.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
 125. Colman GJ, Joyce T: Trends in smoking before, during, and after pregnancy in ten states. *Am J Prev Med*. 2003; 24(1): 29–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
 126. **F** Heil SH, Herrmann ES, Badger GJ, *et al.*: Examining the timing of changes in cigarette smoking upon learning of pregnancy. *Prev Med*. 2014; 68: 58–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
 127. **F** Kitsantas P, Gaffney KF, Wu H, *et al.*: Determinants of alcohol cessation, reduction and no reduction during pregnancy. *Arch Gynecol Obstet*. 2014; 289(4): 771–779.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Kirsten A. Donald**

Division of Developmental Paediatrics, Department of Paediatrics & Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa

Competing Interests: No competing interests were disclosed.

2. **Oscar Garcia-Algar**

Unitat de Recerca Infància i Entorn (URIE), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research